Titlebook: Renal Cell Carcinoma; Molecular Features a Mototsugu Oya Book 2017 Springer Japan KK 2017 Molecular-targeted therapy.TKI.anti-angiogenic ag

只看該作者 · 發(fā)表于 2025-3-23 12:18:46

Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus,ism; the mTOR pathway appears to be deregulated in a number of human malignancies including renal cell carcinoma..To date, two mTOR inhibitors have been registered for the treatment of renal cell carcinoma: temsirolimus (for treatment-na?ve patients with poor prognostic features) and everolimus (for

只看該作者 · 發(fā)表于 2025-3-23 17:51:12

只看該作者 · 發(fā)表于 2025-3-23 19:48:07

只看該作者 · 發(fā)表于 2025-3-23 23:06:08

Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy,t of advanced renal cell carcinoma (RCC). However, in most cases, RCC cells eventually develop drug resistance or drug treatments are stopped because of their adverse events (AEs)..TKIs that are selective for targeted molecules have potent antitumor effects and produce few side effects are ideal. Al

只看該作者 · 發(fā)表于 2025-3-24 03:12:18

只看該作者 · 發(fā)表于 2025-3-24 09:32:05

只看該作者 · 發(fā)表于 2025-3-24 14:04:56

只看該作者 · 發(fā)表于 2025-3-24 14:53:22

只看該作者 · 發(fā)表于 2025-3-24 21:57:34

只看該作者 · 發(fā)表于 2025-3-25 00:33:49

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 10:21
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved